메디채널

공유하기

Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer

2025.09.12 11:00:00

많이 본 기사

더보기

섹션별 최근기사
섹션별 인기기사

경제Uxin to Present at Sidoti September Virtual Investor Conference September 17-18, 2025
엔터Xinhua Silk Road: 제16회 중국 양쯔강 싼샤 국제 관광 축제 이창에서 개막
라이프3Shape Announces Leadership Transition: Rune Fisker Appointed External Executive Advisor to CEO After 25 Years of Pioneering Innovation
스포츠Amazfit Announces Olympic Medalist Grant Fisher as New Brand Ambassador
정치Strider Technologies、NATOの防衛イノベーション・アクセラレーターとの提携を発表
사회SynbioTech's TWK10 Approved to Boost Muscle Strength, The Probiotic Pioneer Marches Toward Southeast Asia Market

발행인 : 최희정 | 편집인 : 김갑성 | 등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 | 주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동) Copyright @메디채널 Corp. All rights reserved.